The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302
Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., & Guengerich, F. P. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22379-5 · Cited by 2,785 · cited 1×
“It is now believed that 8% of the drugs on the market are fully or partially metabolized by CYP2B6 (Treger and Stoll, 2002), and it represents 6% of the total liver P450 content (Stresser and Kupfer, 1999), in contrast to earlier estimates that it represented less than 1% (Shimada et al., 1994).”
ResultStaszewski, S., Morales-Ramirez, J., Tashima, K. T., Rachlis, A., Skiest, D., Stanford, J., Stryker, R., Johnson, P., Labriola, D. F., Farina, D., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912163412501 · Cited by 993
Marzolini, C., Telenti, A., Decosterd, L. A., Greub, G., Biollaz, J., & Buclin, T. (2001) · AIDS · doi:10.1097/00002030-200101050-00011 · Cited by 840
Lang, T., Klein, K., Fischer, J., Nussler, A. K., Neuhaus, P., Hofmann, U., Eichelbaum, M., Schwab, M. G., & Zanger, U. M. (2001) · Pharmacogenetics · doi:10.1097/00008571-200107000-00004 · Cited by 574
Gorski, J. C., Jones, D. R., Haehner-Daniels, B. D., Hamman, M. A., O'Mara, E. M., & Hall, S. D. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90146-1 · Cited by 411
Self-citationChristopher Gorski, J., Hall, S. D., Jones, D. R., & VandenBranden, M. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90543-6 · Cited by 395
Self-citationPhenobarbital Response Elements of Cytochrome P450 Genes and Nuclear Receptors
Sueyoshi, T., & Negishi, M. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.123 · Cited by 362
Faucette, S. R., Hawke, R. L., Lecluyse, E. L., Shord, S. S., Yan, B., Laethem, R. M., & Lindley, C. M. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0026-895x(24)12054-8 · Cited by 353
Human CYP2B6: expression, inducibility and catalytic activities
Gervot, L., Rochat, B., Gautier, J. C., Bohnenstengel, F., Kroemer, H., de Berardinis, V., Martin, H., Beaune, P., & de Waziers, I. (1999) · Pharmacogenetics · doi:10.1097/00008571-199906000-00004 · Cited by 265
Cited by
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
“A major clinical role of CYP2B6 polymorphism was established in HIV therapy, following the identification of CYP2B6 as the major enzyme responsible for 8-hydroxylation of efavirenz and its further hydroxylation to 8, 14-dihydroxyefavirenz (Ward et al., 2003).”
BackgroundIngelman-Sundberg, M., Sim, S. C., Gomez, A., & Rodriguez-Antona, C. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.09.004 · Cited by 1,166
Polymorphism of human cytochrome P450 enzymes and its clinical impact
Zhou, S.-F., Liu, J.-P., & Chowbay, B. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902843483 · Cited by 826
Organic Carbamates in Drug Design and Medicinal Chemistry
Ghosh, A. K., & Brindisi, M. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501371s · Cited by 739
Desta, Z., Ward, B. A., Soukhova, N. V., & Flockhart, D. A. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.065607 · Cited by 645
Self-citationZhou, Y., Ingelman‐Sundberg, M., & Lauschke, V. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.690 · Cited by 583
Inhibition and induction of human cytochrome P450 enzymes: current status
Pelkonen, O., Turpeinen, M., Hakkola, J., Honkakoski, P., Hukkanen, J., & Raunio, H. (2008) · Archives of Toxicology · doi:10.1007/s00204-008-0332-8 · Cited by 569
Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice
Gardiner, S. J., & Begg, E. J. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.6 · Cited by 406
Lamba, V., Lamba, J., Yasuda, K., Strom, S., Davila, J., Hancock, M. L., Fackenthal, J. D., Rogan, P. K., Ring, B., Wrighton, S. A., et al. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.054866 · Cited by 400
Usach, I., Melis, V., & Peris, J. (2013) · Journal of the International AIDS Society · doi:10.7448/ias.16.1.18567 · Cited by 373
Zanger, U. M., & Klein, K. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2013.00024 · Cited by 345
Cottrell, M. L., Hadzic, T., & Kashuba, A. D. M. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0093-2 · Cited by 298
Faucette, S. R., Zhang, T.-C., Moore, R., Sueyoshi, T., Omiecinski, C. J., LeCluyse, E. L., Negishi, M., & Wang, H. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.112136 · Cited by 294
Klein, K., Lang, T., Saussele, T., Barbosa-Sicard, E., Schunck, W.-H., Eichelbaum, M., Schwab, M., & Zanger, U. M. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01213011-200512000-00004 · Cited by 269
Zhou, S.-F., Wang, B., Yang, L.-P., & Liu, J.-P. (2010) · Drug Metabolism Reviews · doi:10.3109/03602530903286476 · Cited by 262
Scott, S. A., Sangkuhl, K., Shuldiner, A. R., Hulot, J.-S., Thorn, C. F., Altman, R. B., & Klein, T. E. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32834d4962 · Cited by 261
Polymorphic CYP2B6: Molecular Mechanisms and Emerging Clinical Significance
Zanger, U. M., Klein, K., Saussele, T., Blievernicht, J., H Hofmann, M., & Schwab, M. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.7.743 · Cited by 258
Haas, D. W., Smeaton, L. M., Shafer, R. W., Robbins, G. K., Morse, G. D., Labbé, L., Wilkinson, G. R., Clifford, D. B., D’Aquila, R. T., De Gruttola, V., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/497610 · Cited by 257
Rotger, M., Tegude, H., Colombo, S., Cavassini, M., Furrer, H., Décosterd, L., Blievernicht, J., Saussele, T., Günthard, H. F., Schwab, M., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100072 · Cited by 257
Efavirenz: what is known about the cellular mechanisms responsible for its adverse effects
Apostolova, N., Blas-Garcia, A., Galindo, M. J., & Esplugues, J. V. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.07.016 · Cited by 49
Metadata
- Authors
- Ward, B. A., Gorski, J. C., Jones, D. R., Hall, S. D., Flockhart, D. A., & Desta, Z.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2003-07
- Volume
- 306
- Issue
- 1
- Pages
- 287-300
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2071086973
- Cited by
- 593
- References
- 28
- FWCI
- 14.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.